Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
DK1-CDG is characterized by muscular hypotonia and ichthyosis. It has been described in four children from two consanguineous families. All the affected children died during early infancy, two from dilated cardiomyopathy. The syndrome is caused by a deficiency in dolichol kinase 1 (DK1), an enzyme involved in the de novo biosynthesis of dolichol phosphate. The mutations identified in the DK1 gene led to a 96 to 98% reduction in DK activity.
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 9:34 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about DK1-congenital disorder of glycosylation
Features include very common findings: Enlarged and weakened heart (dilated cardiomyopathy), Type I transferrin isoform profile, Abnormal circulating enzyme concentration or activity, and Cardiomyocyte hypertrophy; and common findings: Seizure, Low muscle tone (hypotonia), Dry skin, and Failure to thrive and others. 48 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Seizure, Mild global developmental delay, Autistic behavior |
Skin | 5 | Alopecia, Dry skin, Inflammatory abnormality of the skin |
Heart and blood vessels | 5 | Enlarged and weakened heart (dilated cardiomyopathy), Bradycardia, Congestive heart failure |
Muscles | 3 | Low muscle tone (hypotonia), Progressive muscle weakness, Severe muscular hypotonia |
Eyes | 3 | Nystagmus, Strabismus, Visual impairment |
Digestive system | 3 | Diarrhea, Vomiting, Elevated circulating hepatic transaminase concentration |
Growth and development | 2 | Failure to thrive, Short stature |
Head and neck | 2 | Secondary microcephaly, Progressive microcephaly |
Lab test results | 1 | Elevated circulating hepatic transaminase concentration |
DOLK encodes dolichol kinase (538 aa). Catalyzes CTP-mediated phosphorylation of dolichol, the terminal step in de novo dolichyl monophosphate (Dol-P) biosynthesis. Highest expression in Testis (35.3 TPM) and Cells Cultured fibroblasts (32.5 TPM).
DK1-congenital disorder of glycosylation is caused by mutations in the DOLK gene on chromosome 9.
The DOLK protein participates in Defective DOLK causes DOLK-CDG pathway.
DOLK is classified as a druggable target (Enzyme and Kinase categories) with score 0.0.
Genetic testing for DOLK is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for DK1-congenital disorder of glycosylation has been reported in the published literature.
Phenotype severity distribution: 4 very common features, 9 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for DK1-congenital disorder of glycosylation.
207 publications have been identified in PubMed for DK1-congenital disorder of glycosylation. Research spans Review / Meta-Analysis (43%), Basic Science / Preclinical (43%), and Diagnostic / Biomarker (5%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 90 | 43% |
Laboratory research | 89 | 43% |
Testing and diagnosis research | 11 | 5% |
Disease patterns and progression | 10 | 5% |
Patient case studies | 3 | 1% |
New treatment approaches | 2 | 1% |
Other research | 1 | 0% |
Clinical study results | 1 | 0% |
Li P (2026). [PMID: 41316688](https://pubmed.ncbi.nlm.nih.gov/41316688/). *Allergy*. [Review / Meta-Analysis]
Garapati K (2026). [PMID: 41713138](https://pubmed.ncbi.nlm.nih.gov/41713138/). *Mol Genet Metab*. [Diagnostic / Biomarker]
Wen C (2026). [PMID: 41991450](https://pubmed.ncbi.nlm.nih.gov/41991450/). *Dig Liver Dis*. [Basic Science / Preclinical]
Tachida Y (2026). [PMID: 41917388](https://pubmed.ncbi.nlm.nih.gov/41917388/). *Adv Exp Med Biol*. [Review / Meta-Analysis]
Ünsal Y (2026). [PMID: 39975416](https://pubmed.ncbi.nlm.nih.gov/39975416/). *J Clin Res Pediatr Endocrinol*. [Review / Meta-Analysis]
Zhu N (2026). [PMID: 41177858](https://pubmed.ncbi.nlm.nih.gov/41177858/). *Sci China Life Sci*. [Basic Science / Preclinical]
Driesen K (2026). [PMID: 41570364](https://pubmed.ncbi.nlm.nih.gov/41570364/). *Mol Genet Metab*. [Diagnostic / Biomarker]
Fu B (2026). [PMID: 41559085](https://pubmed.ncbi.nlm.nih.gov/41559085/). *Nat Commun*. [Basic Science / Preclinical]
Yi L (2026). [PMID: 41264770](https://pubmed.ncbi.nlm.nih.gov/41264770/). *Protein Cell*. [Review / Meta-Analysis]
Weger M (2026). [PMID: 41644694](https://pubmed.ncbi.nlm.nih.gov/41644694/). *Nat Metab*. [Basic Science / Preclinical]